167 related articles for article (PubMed ID: 21710755)
1. [Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].
Qiao X; Zhang W; Li Z; Zeng Y
Zhongguo Zhong Yao Za Zhi; 2011 Mar; 36(6):806-9. PubMed ID: 21710755
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
3. [Progress in the study of HIV-1 Vif and related inhibitors].
Li ZY; Zhan P; Liu XY
Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
[TBL] [Abstract][Full Text] [Related]
4. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
6. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
7. Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.
Romani B; Engelbrecht S; Glashoff RH
Arch Virol; 2009; 154(10):1579-88. PubMed ID: 19669862
[TBL] [Abstract][Full Text] [Related]
8. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
10. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
11. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
13. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
14. Small molecules that inhibit Vif-induced degradation of APOBEC3G.
Matsui M; Shindo K; Izumi T; Io K; Shinohara M; Komano J; Kobayashi M; Kadowaki N; Harris RS; Takaori-Kondo A
Virol J; 2014 Jul; 11():122. PubMed ID: 24986077
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
Kremer M; Schnierle BS
Curr HIV Res; 2005 Oct; 3(4):339-44. PubMed ID: 16250885
[TBL] [Abstract][Full Text] [Related]
16. Protecting APOBEC3G: a potential new target for HIV drug discovery.
Stopak K; Greene WC
Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
[TBL] [Abstract][Full Text] [Related]
17. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
Huang W; Zuo T; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
Mol Divers; 2013 May; 17(2):221-43. PubMed ID: 23378232
[TBL] [Abstract][Full Text] [Related]
19. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
